✦ LIBER ✦

Rapamycin passes the torch: a new generation of mTOR inhibitors

✍ Scribed by Benjamin, Don; Colombi, Marco; Moroni, Christoph; Hall, Michael N.

Book ID: 111885900
Publisher: Nature Publishing Group
Year: 2011
Tongue: English
Weight: 772 KB
Volume: 10
Category: Article
ISSN: 1474-1776
DOI: 10.1038/nrd3531

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PI3K and mTOR inhibitors — a n

PI3K and mTOR inhibitors — a new generation of targeted anticancer agents

✍ Saskia Brachmann; Christine Fritsch; Saveur-Michel Maira; Carlos García-Echeverr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Targeting the mammalian target of rapamy

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

✍ Chan, S 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 89 KB

A pilot trial of the mTOR (mammalian tar

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

✍ Thomas Decker; Michael Sandherr; Katharina Goetze; Madlen Oelsner; Ingo Ringshau 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 151 KB

Pyrimidoaminotropanes as Potent, Selecti

Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR)

✍ Estrada, Anthony A.; Shore, Daniel G.; Blackwood, Elizabeth; Chen, Yung-Hsiang; 📂 Article 📅 2013 🏛 American Chemical Society 🌐 English ⚖ 938 KB

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Phosphoinositide 3-kinase in Health and Disease Volume 347 || New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)

✍ Rommel, Christian; Vanhaesebroeck, Bart; Vogt, Peter K. 📂 Article 📅 2010 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 321 KB

PI3K has become a very intense area of research, with over 2000 publications on PI3K in PubMed for 2009 alone. The expectations for a therapeutic impact of intervention with PI3K activity are high, and progress in the clinical arena is being monitored by many. However, targeted therapies almost inva

52 Discovery of novel fused thiadiazoles

52 Discovery of novel fused thiadiazoles as potent inhibitors of phosphoinositide-3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR)

✍ J. Pastor; G. Kurz; M.R. Rico Ferreira; D. Soilan; M.A. Ortega; S. Martinez; O. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB